Display Settings:

Format

Send to:

Choose Destination

    Gut. 1983 Aug;24(8):713-7.

    Clostridium difficile and inflammatory bowel disease.

    Greenfield C, Aguilar Ramirez JR, Pounder RE, Williams T, Danvers M, Marper SR, Noone P.

    Stools from 109 patients with inflammatory bowel disease (13.4%) contained Clostridium difficile or its toxin, an incidence similar to the stools of 99 control patients with diarrhoea (11.9%), but significantly higher than the stools of 77 control patients with a normal bowel habit (1.4%). Sixty-six per cent of the diarrhoea controls, but only 11% of the inflammatory bowel disease patients, reported recent antibiotic use: however, 67% of inflammatory bowel disease patients were taking sulphasalazine. The presence of Cl difficile in the stool was not related to the clinical assessment of inflammatory bowel disease relapse, but it was related to hospital admission. During the one year study, 31 of the 109 patients (28%) with inflammatory bowel disease had one or more stool samples that were positive for Cl difficile.

    PMID: 6135648 [PubMed - indexed for MEDLINE]

    PMCID: PMC1420228

    Supplemental Content

    Click here to read Click here to read

    Patient drug information

    • Sulfasalazine (Azulfidine®, Azulfidine® EN-tabs®)

      Sulfasalazine is used to treat bowel inflammation, diarrhea (stool frequency), rectal bleeding, and abdominal pain in patients with ulcerative colitis, a condition in which the bowel is inflamed. Sulfasalazine delayed-re...